IOVA FINAL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important July 14 Deadline in Securities Class Action – IOVA

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Iovance Biotherapeutics, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the Iovance securities is from May 9, 2024, to May 8, 2025, inclusive [1]. - Investors who purchased Iovance securities during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by July 14, 2025 [2]. Group 2: Allegations Against Iovance - The lawsuit alleges that Iovance made false and misleading statements regarding the effectiveness of new Authorized Treatment Centers (ATCs) in treating patients with Amtagvi [3]. - It is claimed that the sales team and new ATCs were ineffective in patient identification and selection, leading to higher patient drop-offs [3]. - These issues resulted in increased costs and lower revenue, as ATCs could not keep pace with the manufactured product, contradicting the positive statements made by the defendants about Iovance's business and prospects [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has consistently ranked highly in terms of class action settlements [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4].